
    
      The primary objective of this clinical trial is to assess the response rate and PFS in
      previously treated breast cancer patients. Additional objectives include the pharmacokinetics
      of multiple ascending doses of SM-88, a cocktail combination of 4 drugs being developed for
      the indication of metastatic breast cancer. Secondary objectives of this study include an
      assessment of safety and tolerability of ascending doses of orally administered SM-88.
      Additional response data will also be collected.
    
  